Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

BRUSSELS, November 3 /PRNewswire/ -- The International Diabetes Federation (IDF) announced today that Ms Ann Keeling has joined the organization as Chief Executive Officer/Executive Director.

The International Diabetes Federation, headquartered in Brussels, Belgium, is an umbrella organization of over 200 diabetes associations worldwide. It is the global advocate for the more than 250 million people with diabetes, their families, and healthcare providers.

BASEL, Switzerland, November 1 /PRNewswire/ --

- Three New Studies Presented at AASLD Demonstrate Efficacy and Safety of Extended Treatment in Non-Responders, Relapsers and Slow-Responders

Cure rates for certain groups of difficult-to-treat hepatitis C patients can be improved significantly by extending the treatment period with PEGASYS(R) (peginterferon alfa-2a (40KD)) and COPEGUS(R) (ribavirin) to 72 weeks, according to new studies being presented at AASLD this week in San Francisco.

BASEL, Switzerland, November 1 /PRNewswire/ -- A new, independently-conducted study being presented at AASLD shows that PEGASYS(R) (peginterferon alfa-2a (40KD)) regimens result in higher cure rates for hepatitis C patients compared to regimens with another pegylated interferon.(1)

Comparing Today's Standard Treatment Regimens: The Milan Safety Tolerability Study

MCKINNEY, Texas, October 31 /PRNewswire/ --

Torchmark Corporation (NYSE: TMK) announced that its Board of Directors has declared a quarterly dividend of US$.14 per share on all of the outstanding common stock of the Company held of record as of the close of business of the Company's transfer agent on January 2, 2009. The dividend will be paid on January 30, 2009.

NEW YORK, October 31 /PRNewswire/ --

- Culture+Travel to be integrated as a new section on ARTINFO.com, Art+Auction and Modern Painters.

The world's leading web site for art and culture has been re-designed to provide a more comprehensive information resource of the dynamic global art world and art markets.

Enhancements to the site include new content from Louise Blouin Media print publications Art+Auction, Modern Painters and Gallery Guide plus Art Sales Index's database of over 3.5 million auction price results. Additionally, the redesign includes Culture + Travel, LBM's unique take on the world's most interesting cultural destinations, which now appears both in its own online section and alongside original and related ARTINFO.com articles.

COPENHAGEN, Denmark, October 31 /PRNewswire/ --

- DoctorConsult in Germany Marks First of Several Localized Workflow Solutions That Improve Clinician Decision Making and Health Care Business Performance

With a deep understanding of healthcare workflow and more than a century of experience as a global medical publisher, Elsevier is increasing its efforts to provide interactive clinical reference and clinical decision support (CDS) tools to new markets in Europe. With the launch of DoctorConsult - the German language version of MD Consult ( http://www.doctorconsult.de) -- Elsevier becomes the first multi-lingual professional clinical reference product provider.